News for LMNL Stock

LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP Liminal BioSciences Reports Second Quarter Financial Results 2023 Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders Liminal BioSciences Provides R&D Update Liminal BioSciences Reports First Quarter Financial Results 2023 The Special Committee of the Board of Directors of Liminal Biosciences Retains an Independent Financial Advisor in Response to Unsolicited Non-Binding Transaction Proposal Liminal Biosciences Confirms Receipt of Unsolicited Non-Binding Transaction Proposal Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023 Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement Liminal BioSciences Announces Reverse Stock Split Liminal BioSciences to Present at BIO CEO & Investor Conference Liminal BioSciences Announces Priorities For 2023 Liminal BioSciences Announces Holding of Special Meeting of Shareholders Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022 Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Investment Conference Liminal BioSciences Announces Termination of Legacy CDMO Contract Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights Liminal BioSciences Announces Discontinuation of Fezagepras Development Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022 Liminal Biosciences to Present at Upcoming Investor Conferences Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP Liminal BioSciences Announces Strategic Priorities For 2022 Liminal BioSciences Reports Third Quarter 2021 Financial Results Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business Liminal BioSciences Announces Closing of Sale of Priority Review Voucher Liminal BioSciences Reports Second Quarter 2021 Financial Results Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM) Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh) Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion Liminal BioSciences Reports First Quarter 2021 Financial Results Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference Liminal BioSciences Reports Third Quarter Financial Results Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLA Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition Liminal BioSciences Announces Private Placement Financing of USD$30 Million Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®(plasminogen) Liminal BioSciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen) for Treatment of Congenital Plasminogen Deficiency Liminal BioSciences Announces New Appointments to its Board of Directors Liminal BioSciences reports financial results for Q2-2020 Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020